RESUMO

EGFR signaling is an important regulator of SARS-CoV induced lung damage, inflammation and fibrosis. Nimotuzumab is a humanized anti-EGFR antibody registered for several cancer indications. An expanded access study was conducted to evaluate the safety and recovery rate of severe and critical patients with confirmed SARS-CoV-2 infection, treated with nimotuzumab in combination with the standard of care in the real-world scenario. The antibody was administered as an intravenous infusions every 72 h, up to 5 doses. In order to assess the impact of nimotuzumab, the recovery rate was compared with a paired retrospective cohort. Control patients received standard treatment according the national protocol but not nimotuzumab. Overall, 1,151 severe or critical patients received nimotuzumab in 21 hospitals of Cuba. Median age was 65 and 773 patients had at least one comorbidity. Nimotuzumab was very well-tolerated and mild or moderate adverse events were detected in 19 patients. 1,009 controls matching with the nimotuzumab patients, were selected using a "propensity score" method. The 14-day recovery rate of the nimotuzumab cohort was 72 vs. 42% in the control group. Controls had a higher mortality risk (RR 2.08, 95% CI: 1.79, 2.38) than the nimotuzumab treated patients. The attributable fraction was 0.52 (95% CI: 0.44%; 0.58), and indicates the proportion of deaths that were prevented with nimotuzumab. Our preliminary results suggest that nimotuzumab is a safe antibody that can reduce the mortality of severe and critical COVID-19 patients.

Assuntos

RESUMO

INTRODUCTION: Head and neck cancer patients are at high risk of SARS-CoV-2 infection; surgery in them involves risk for patients, surgeons, health personnel, medical institutions and society, since it is associated with prolonged and inadvertent production of aerosols and emergency procedures that facilitate the breach of protective measures by health personnel. OBJECTIVE: To find out if pulmonary tomographic findings are sufficient to preoperatively identify patients with COVID-19. METHODS: Retrospective, cross-sectional, analytical study of patients with cervical-facial neoplasms who were candidates for surgery, preoperatively evaluated by simple chest computed tomography based on the CO-RADS classification. In CO-RADS ≥ 3 patients, surgery was suspended and PCR was performed using nasopharyngeal swab. RESULTS: 322 patients were included, all without COVID-19 symptoms. Tomography was positive in 35 (10.87%); in 30, nasopharyngeal swab was performed: 28 were negative and two were positive; none developed COVID-19 symptoms. CONCLUSIONS: Chest tomography is not useful as the only preoperative screening procedure for COVID-19, since its findings are nonspecific, with a high rate of false-positive results. Clinical evaluation, with PCR and tomography, is the best form of preoperative screening.

INTRODUCCIÓN: Los pacientes con cáncer de cabeza y cuello tienen alto riesgo de infección por SARS-CoV-2; la cirugía en ellos implica riesgo para pacientes, cirujanos, personal de salud, institución médica y sociedad, ya que se asocia a aerosolización prolongada e inadvertida y a procedimientos de urgencia que facilitan la ruptura de las medidas de protección del personal de salud. OBJETIVO: Conocer si los hallazgos tomográficos pulmonares son suficientes para identificar en forma preoperatoria a los pacientes con COVID-19. MÉTODOS: Estudio retrospectivo, transversal y analítico de pacientes con neoplasias cervicofaciales candidatos a cirugía, evaluados preoperatoriamente mediante tomografía axial computarizada simple de tórax con base en la clasificación CO-RADS. En los pacientes CO-RADS ≥ 3 se suspendió la cirugía y se realizó PCR por hisopado nasofaríngeo. RESULTADOS: Se incluyeron 322 pacientes, todos sin síntomas de COVID-19. La tomografía fue positiva en 35 (10.87 %); en 30 se efectuó hisopado nasofaríngeo: 28 fueron negativos y dos, positivos; ninguno desarrolló síntomas de COVID-19. CONCLUSIONES: La tomografía torácica no es útil como procedimiento único de tamizaje preoperatorio de COVID-19, ya que sus hallazgos son inespecíficos, con tasa alta de resultados falsos-positivos. La evaluación clínica, con PCR y tomografía es la mejor forma de pesquisa preoperatoria.

Assuntos

RESUMO

Resumen Introducción: Los pacientes con cáncer de cabeza y cuello tienen alto riesgo de infección por SARS-CoV-2; la cirugía en ellos implica riesgo para pacientes, cirujanos, personal de salud, institución médica y sociedad, ya que se asocia a aerosolización prolongada e inadvertida y a procedimientos de urgencia que facilitan la ruptura de las medidas de protección del personal de salud. Objetivo: Conocer si los hallazgos tomográficos pulmonares son suficientes para identificar en forma preoperatoria a los pacientes con COVID-19. Métodos: Estudio retrospectivo, transversal y analítico de pacientes con neoplasias cervicofaciales candidatos a cirugía, evaluados preoperatoriamente mediante tomografía axial computarizada simple de tórax con base en la clasificación CO-RADS. En los pacientes CO-RADS ≥ 3 se suspendió la cirugía y se realizó PCR por hisopado nasofaríngeo. Resultados: Se incluyeron 322 pacientes, todos sin síntomas de COVID-19. La tomografía fue positiva en 35 (10.87 %); en 30 se efectuó hisopado nasofaríngeo: 28 fueron negativos y dos, positivos; ninguno desarrolló síntomas de COVID-19. Conclusiones: La tomografía torácica no es útil como procedimiento único de tamizaje preoperatorio de COVID-19, ya que sus hallazgos son inespecíficos, con tasa alta de resultados falsos-positivos. La evaluación clínica, con PCR y tomografía es la mejor forma de pesquisa preoperatoria.

Abstract Introduction: Head and neck cancer patients are at elevated risk of SARS-CoV-2 infection; surgery in them involves risk for patients, surgeons, health personnel, medical institutions and society, since it is associated with prolonged and inadvertent production of aerosols and emergency procedures that facilitate the breach of protective measures by health personnel. Objective: To find out if pulmonary tomographic findings are sufficient to preoperatively identify patients with COVID-19. Methods: Retrospective, cross-sectional, analytical study of patients with cervical-facial neoplasms who were candidates for surgery, preoperatively evaluated by simple chest computed tomography based on the CO-RADS classification. In CO-RADS ≥ 3 patients, surgery was suspended and PCR was performed using nasopharyngeal swab. Results: 322 patients were included, all without COVID-19 symptoms. Tomography was positive in 35 (10.87%); in 30, nasopharyngeal swab was performed: 28 were negative and two were positive; none developed COVID-19 symptoms. Conclusions: Chest tomography is not useful as the only preoperative screening procedure for COVID-19, since its findings are nonspecific, with a high rate of false-positive results. Clinical evaluation, with PCR and tomography, is the best form of preoperative screening.

Assuntos

RESUMO

OBJECTIVES: The COVID-19 diagnosis is difficult and ambiguous due to nonspecific symptoms. Further, data from Mexico arehospitable population-based without signs and symptoms information. Thus, this work aims to provide epidemiology information about the burden of COVID-19 in Mexican outpatients and to identify symptomatic COVID-19 profiles that could help in the early diagnosis of the disease. METHODS: From June to September, epidemiological, clinical, and demographic data of 482,413 individuals diagnosed by RT-PCR test for SARS-CoV-2 in Salud Digna clinics were collected. RESULTS: We observed a 41% incidence of SARS-CoV-2 infections with a mean age of 36 years and with young adults (20-40 years) being the most affected. Among occupations, delivery persons (OR 1.38) or informal traders (OR 1.33) had a higher risk of COVID-19. Moreover, 13% of SARS-CoV-2 infections were in presymptomatic patients. Finally, we identified three different symptomatic profiles (common, respiratory, and gastrointestinal) associated with COVID-19. CONCLUSION: The incidence of SARS-CoV-2 was high among outpatients with a significant proportion of presymptomatic carriers, and thus it is necessary to increase testing and continue SARS-CoV-2 surveillance with a better description of signs and symptoms; in this regard, we identified three symptomatic profiles that could help in the diagnosis of COVID-19.

Assuntos

RESUMO

The use of embodied conversational agents in mental health has increased in the last years. Several studies exist describing the benefits and advantages of this technology as a complement to psychotherapeutic interventions for the prevention and treatment of depression, anxiety, or post-traumatic stress disorder, to name a few. A small number of these works implement capabilities in the virtual agent focused on the detection and prevention of suicidality risks. The work presented in this paper describes the development of an embodied conversational agent used as the main interface in HelPath, a mobile-based application addressed to individuals detected with any of the suicidal behaviours: ideation, planning or attempt. The main objective of HelPath is to continuously collect user's information that, complemented with data from the electronic health record, supports the identification of risks associated with suicidality. Through the virtual agent, the users also receive information and suggestions based on cognitive behaviour therapy that would help them to maintain a healthy condition. The paper also presents the execution of an exploratory pilot to assess the acceptability, perception and adherence of users towards the virtual agent. The obtained results are presented and discussed, and some actions for further improvement of the embodied conversational agent are also identified.

Assuntos

RESUMO

Dengue virus is the most important arbovirus that affects humans, and it can establish persistent infections, especially in insect-derived cell cultures. Defective viral genomes have been implicated in the establishment and maintenance of persistent infections with several flaviviruses; however, there exists almost no information concerning defective dengue virus genomes. Here, we report the detection of defective dengue 2 virus genomes in persistently infected mosquito C6/36 cells. The defective viral genomes were detected at a low ratio compared with the wild-type genome. Deletions of approximately 147 residues (222-368) were found in the E protein, and these mainly affected domain III (73 %) of the protein; deletions of approximately 153 residues (4-156) and 228 residues (597-825) were found in the methyltransferase and polymerase domains, respectively, of the NS5 protein. The truncated versions of NS5 could be detected by western blot only in the protein extracts derived from persistently infected cells.

Assuntos